A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone

JIANQING LIN,a,b SHEEL A. PATEL,a ASHWIN R. SAMA,a JEAN H. HOFFMAN-CENSITS,a BROOKE KENNEDY,a DEBORAH KILPATRICK,a ZHONG YE,a HUSHAN YANG,a ZHAOMEI MU,a BENJAMIN LEIBY,a NANCY LEWIS,a MASSIMO CRISTOFANILLI,c WILLIAM KEVIN KELLYa

aThomas Jefferson University, Philadelphia, Pennsylvania, USA; bGeorge Washington University, Washington, D.C., USA; cNorthwestern University, Evanston, Illinois, USA

TRIAL INFORMATION

- ClinicalTrials.gov Identifier: NCT01848067
- Sponsor: Thomas Jefferson University
- Principal Investigator: Jianqing Lin
- IRB Approved: Yes

LESSONS LEARNED

- Patients with metastatic castration-resistant prostate cancer did not tolerate the combination of alisertib with abiraterone and prednisone.
- There was no clear signal indicating that adding alisertib might be beneficial for those patients progressing on abiraterone.

ABSTRACT

Background. We hypothesized that Aurora A kinase (AK) contributes to castrate resistance in prostate cancer (PCa) and that inhibiting AK with alisertib can resensitize PCa cells to androgen receptor (AR) inhibitor abiraterone.

Methods. This was a phase I/II trial to determine the safety and efficacy of alisertib when given in combination with abiraterone plus prednisone (AP). Metastatic castration-resistant prostate cancer (mCRPC) patients were treated with dose escalation (alisertib at 30, 40, and 50 mg orally b.i.d., days 1–7 every 21 days) per standard 3 + 3 design.

Results. Nine of 43 planned subjects were enrolled. The maximum tolerated dose (MTD) was not reached, and the dose-limiting toxicities (DLTs) included neutropenic fever (1 of 9), neutropenia (1 of 9), fatigue with memory impairment (1 of 9), and diarrhea/mucositis (1 of 9). No prostate-specific antigen (PSA) decrease or circulating tumor cell (CTC) changes were observed during the study. Pharmacodynamically, adding alisertib did not affect total testosterone or dehydroepiandrosterone (DHEA) levels. There was some change in neuroendocrine markers after therapy. Mean duration on study was 2.5 months. The trial was terminated early.

Conclusion. A tolerable dose of alisertib in combination with AP in mCRPC was not established in this study. There was no clear signal indicating that alisertib might be beneficial for patients with mCRPC progressing on abiraterone.

DISCUSSION

Abiraterone acetate is active and approved for use in patients with metastatic castration-resistant prostate cancer [1, 2], but resistance does develop, and the mechanism of drug resistance is under active investigation [3]. Preclinical studies have shown AK as a potential target for advanced PCa, especially for PCa with neuroendocrine differentiation. We investigated whether the addition of alisertib, an AK inhibitor, to an AP regimen was tolerable and effective to reverse resistance to abiraterone.

The trial was terminated early because of toxicity and lack of clinical benefit. The first three patients in cohort 1 (30 mg b.i.d., days 1–7 every 21 days) did not experience a DLT. Two patients experienced DLTs in cohort 2 (40 mg level) (fatigue with memory impairment or neutropenic fever), resulting in dose de-escalation. Three additional patients were treated at 30 mg b.i.d., and two developed DLTs (neutropenia and diarrhea/mucositis). Evaluation of side-effect profile among the nine patients demonstrated poor tolerability of alisertib and abiraterone/prednisone combination. Bone marrow suppression is a known side effect from alisertib [4, 5], but the rate of grade 3/4 toxicities was higher in our study compared with others. It is important to note that previous studies used alisertib as monotherapy in solid tumors. To improve patient tolerance, it might be reasonable to use a...
different dose and schedule for patients with relatively slow-growing tumors such as prostate cancer.

The efficacy is difficult to assess in this phase I trial. Three patients were taken off the study because of disease progression. Seven (of 9) patients had an increase in PSA during the study. Four (of 9) patients in the trials had $5 \text{ CTCs at baseline}$, but no conversion was observed at the end of therapy. Mean duration on the study was 2.5 months. These results suggest an unfavorable efficacy-to-toxicity ratio for this combination. The trial was prematurely terminated, and the phase II portion was not performed.

From measuring the total testosterone and DHEA levels during the study, we believe alisertib does not interfere with the ability of abiraterone to inhibit biosynthesis of androgens. For neuroendocrine biomarkers, we observed three (of nine) patients who had a sustained decreased in chromogranin A levels and four (of nine) patients who had a decrease in neuron-specific enolase levels. The significance of these changes is not clear, given the small sample size of the study. Fluorescence in situ hybridization analysis of collected CTCs did not demonstrate AK amplification. Further study is certainly needed to make any conclusions.

In summary, adding alisertib to abiraterone regimen seems intolerable in mCRPC. The optimal dose and schedule of alisertib could not be determined. There was no clear signal indicating that alisertib might be beneficial for patients with mCRPC progressing on abiraterone, and further development of this treatment combination is not warranted.

| Dose level | Dose of drug: MLN 8237 | Number enrolled | Number evaluable for toxicity | Number with a dose-limiting toxicity | Dose-limiting toxicity information |
|------------|------------------------|-----------------|-----------------------------|-------------------------------------|----------------------------------|
| 0          | 20 mg p.o. b.i.d., days 1–7 every 21 days | 0               | 0                           | 0                                   | None                             |
| 0          | 30 mg p.o. b.i.d., days 1–7 every 21 days | 3               | 3                           | 0                                   | None                             |
| 1          | 40 mg p.o. b.i.d., days 1–7 every 21 days | 3               | 3                           | 2                                   | Grade 3 fatigue; grade 4 white blood cell decrease |
| 0*         | 30 mg p.o. b.i.d., days 1–7 every 21 days | 3               | 3                           | 3                                   | Grade 4 febrile neutropenia; grade 3 mucositis |

*First cohort treated at level 0 with no dose-limiting toxicities. Second cohort treated at level 1 with two dose-limiting toxicities. Per protocol, dose de-escalation to level zero with three additional subjects.
Dose Level 1: Alisertib, 20 mg p.o. b.i.d., days 1–7 every 21 days
Dose Level 0 (starting): Alisertib, 30 mg p.o. b.i.d., days 1–7 every 21 days
Dose Level 1: Alisertib, 40 mg p.o. b.i.d., days 1–7 every 21 days
Dose Level 2: Alisertib, 50 mg p.o. b.i.d., days 1–7 every 21 days

The first cohort was treated at dose level 0 with no DLTs. The second cohort was treated at dose level 1 with two DLTs. Per protocol, dose de-escalation was to level 0 with three additional subjects.

**PATIENT CHARACTERISTICS**

| **Number of patients, male** | 9 |
|-------------------------------|---|
| **Number of patients, female** | 0 |
| **Stage**                     | Stage IV, Metastatic |
| **Median (range):**           | 68 (62–82) |
| **Number of prior systemic therapies** | Median (range): 1 (1–2) |
| **Performance Status: ECOG**  | 0 — 7 |
|                               | 1 — 2 |
|                               | 2 — 0 |
|                               | 3 — 0 |
|                               | Unknown — 0 |
| **Cancer types or histologic subtypes** | Adenocarcinoma of prostate: 9 |

**PRIMARY ASSESSMENT METHOD**

| **Number of patients screened** | 9 |
| **Number of patients enrolled** | 9 |
| **Number of patients evaluable for toxicity** | 9 |
| **Number of patients evaluated for efficacy** | 9 |
| **Evaluation method**            | Clinic visit at 12 weeks or progression: CT/MRI Abd and Pelvis; CT of chest or CXR; Bone Scan; PSA; Androgen Panel |
| **Response assessment CR**       | 0 |
| **Response assessment PR**       | 0 |
| **Response assessment SD**       | 0 |
| **Response assessment PD**       | n = 3 |
| **Response assessment OTHER**    | n = 6 |

**ADVERSE EVENTS**

| **Name**            | **Fatigue** | **Mucositis oral** | **Alopecia** | **Dizziness** | **Memory impairment** | **Diarrhea** | **Nausea** | **Dyspepsia** | **Anorexia** | **Constipation** | **Rectal pain** | **Confusion** | **Headache** | **Personality change** |
|---------------------|-------------|--------------------|--------------|---------------|----------------------|--------------|------------|--------------|--------------|-------------------|-----------------|---------------|-------------|----------------------|
|                     | 22%         | 67%                | 0%           | 11%           | 0%                  | 0%           | 0%         | 0%           | 0%           | 0%                | 0%              | 0%            | 0%          | 0%                   |
| *NC/NA*             | 1           | 2                  | 3            | 4             | 5                   | All Grades   | 78%        | 44%          | 22%          | 11%               | 22%            | 11%           | 0%          | 0%                   |

©AlphaMed Press 2016
Dyspnea 89% 11% 0% 0% 0% 0% 11%
Electrocardiogram QT corrected interval prolonged 89% 11% 0% 0% 0% 0% 11%
Hypertension 89% 11% 0% 0% 0% 0% 11%
Pharyngitis 89% 11% 0% 0% 0% 0% 11%
Skin hyperpigmentation 89% 11% 0% 0% 0% 0% 11%
Palmar-plantar erythrodysesthesia syndrome 89% 11% 0% 0% 0% 0% 11%
Rash maculo-papular 89% 11% 0% 0% 0% 0% 11%
Pruritus 89% 11% 0% 0% 0% 0% 11%
Urinary tract infection 89% 11% 0% 0% 0% 0% 11%
Hypocalcemia 67% 33% 0% 0% 0% 0% 33%
Hypokalemia 78% 22% 0% 0% 0% 0% 22%
Hyponatremia 89% 11% 0% 0% 0% 0% 11%
Hyperglycemia 67% 0% 11% 11% 11% 0% 33%
White blood cell decreased 45% 0% 44% 0% 11% 0% 55%
Anemia 56% 0% 44% 0% 0% 0% 44%
Neutrophil count decreased 67% 0% 22% 11% 0% 0% 33%
Platelet count decreased 78% 11% 0% 11% 0% 0% 22%
Febrile neutropenia 89% 0% 0% 0% 11% 0% 11%

Adverse Events Legend
*No Change From Baseline/No Adverse Event

### Serious Adverse Events

| Name             | Grade | Attribution |
|------------------|-------|-------------|
| Neutropenic Fever| 4     | Probable    |

### Dose-Limiting Toxicities

| Dose level | Dose of drug: MLN 8237 | Number enrolled | Number evaluable for toxicity | Number with a dose-limiting toxicity | Dose-limiting toxicity information |
|------------|-------------------------|-----------------|------------------------------|--------------------------------------|-----------------------------------|
| −1         | 20 mg p.o. b.i.d., days 1–7 every 21 days | 0               | 0                            | 0                                    | No data                           |
| 0          | 30 mg p.o. b.i.d., days 1–7 every 21 days | 3               | 3                            | 0                                    | No dose-limiting toxicity         |
| 1          | 40 mg p.o. b.i.d., days 1–7 every 21 days | 3               | 3                            | 2                                    | Grade 3 fatigue; grade 4 white blood cell decrease |
| 0*         | 30 mg p.o. b.i.d., days 1–7 every 21 days | 3               | 3                            | 3                                    | Grade 4 febrile neutropenia; grade 3 mucositis |

*First cohort treated at dose level 0 with no dose-limiting toxicities. Second cohort treated at dose level 1 with two dose-limiting toxicities. Per protocol, dose de-escalation to level 0 with three additional subjects.

### Assessment, Analysis, and Discussion

Abiraterone acetate is active and approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) [1, 2]. Unfortunately, disease progression inevitably occurs, and patients require additional therapy, which remains an unmet medical need. The mechanism of resistance to abiraterone is not clear and is still under active investigation [3]. It is widely accepted that prostate cancer (PCa) is composed of heterogeneously distinct cell subtypes, including neuroendocrine prostate cancer (NEPC). NEPC is generally considered an aggressive and lethal variant of PCa that most commonly arises from existing PCa [6]. Clinically, NEPC often has high serum levels of chromogranin A (CgA) and neuron-specific enolase (NSE) [7]. The presence of the neuroendocrine (NE) tumor subpopulation can be gauged noninvasively by measuring circulating levels of secretory products, primarily CgA [8]. Increased plasma CgA was observed in 64.3% of patients with CRPC [9]. Increased NSE was seen in 35% of patients [10]. These NEPC can be considered to be castration-resistant and androgen receptor (AR)-independent because AR signaling is not a key player for survival of these cells [11, 12]. The development of the NE features (transformation) in androgen-deprived conditions may contribute to castrate resistance and/or abiraterone resistance. Molecularly, Aurora Kinase (AK) (and concurrent MYCN oncogene) amplification was identified by
fluorescence in situ hybridization (FISH) in 75% of primary PCa of patients with NEPC (>95% cells) [11]. By using tissue biopsies from metastatic sites, up to 53% metastatic PCa were found to harbor AK amplification [11].

In vitro studies support the fact that there is a functional relationship between AK and PCa: (a) AK is overexpressed in PCa, especially in anti-androgen-resistant PCa [13, 14]; (b) AK phosphorylates and interacts with AR, enhancing AR DNA binding [15]; (c) AK induces cell growth in the presence and absence of androgen; (d) AK induces/enhances AR activity and potentiates androgen action in AR; and (e) targeting AK reverses the androgen-independent phenotype in vitro [15]. Features of mCRPC likely include AK (and concurrent MYCN) amplification/overexpression with NE phenotype. AK is potentially an important drugable target for CRPC with or without neuroendocrine differentiation. Therefore, we investigated whether mCRPC is sensitive to AK suppression by alisertib, especially in the subgroup of patients with neuroendocrine phenotype. We hypothesized that adding alisertib to the existing androgen-deprivation therapy regimen may reverse the resistance to abiraterone.

We designed a phase I/II, open-label, single-institution trial to determine the safety and efficacy of the AK inhibitor alisertib when given in combination with abiraterone plus prednisone (AP). In the phase I portion, we evaluated the maximum tolerated dose of alisertib. In the phase II study, we planned to evaluate the proportion of patients who had no disease progression after alisertib is added to abiraterone and prednisone.

The trial was terminated early because of toxicity and lack of clinical benefit. The first three patients in cohort 1 (30 mg b.i.d., days 1–7 every 21 days) did not experience a dose-limiting toxicity (DLT). Two patients experienced DLTs in cohort 2 (fatigue with memory impairment and neutropenic fever), resulting in dose de-escalation. Three additional patients were treated at 30 mg b.i.d., and two developed DLTs (neutropenia and diarrhea/mucositis). Evaluation of the side-effect profile among the nine patients demonstrated poor tolerability of the alisertib and abiraterone/prednisone combination. Five (of 9) patients required a treatment delay. Bone marrow suppression is a known side effect from alisertib [4, 5], and although the rate of grade 3/4 toxicities was higher in our study compared with others, it is important to note that previous studies used alisertib as monotherapy. To improve patient tolerance, it might be reasonable to use a different dose and schedule for patients with relatively slow-growing tumors such as prostate cancer.

The efficacy of alisertib and abiraterone is difficult to assess in this phase I trial. Three patients were taken off the study because of disease progression. Seven (of 9) patients had an increase in prostate-specific antigen (PSA) during the study. The effect of alisertib on circulating tumor cell (CTC) enumeration before and after treatment was also measured. Four (of 9) patients in the trials had ≥5 CTCS at baseline, but no conversion was observed at the end of therapy. These results suggest an unfavorable efficacy to toxicity ratio of alisertib with abiraterone and prednisone. Therefore, the trial was terminated earlier, and the phase II portion was not performed.

We looked at the possible pharmacodynamic interactions between alisertib and abiraterone. The addition of alisertib did not significantly affect the total testosterone and dehydroepiandrosterone (DHEA) levels. This suggests that alisertib does not interfere with the ability of abiraterone to inhibit the biosynthesis of androgens.

For neuroendocrine biomarkers, we observed 3 (of 9) patients who had a sustained decrease in chromogranin A levels and 4 (of 9) patients who had a decrease in neuron-specific enolase levels. The significance of these changes is not clear, given the small sample size of the study. FISH analysis of collected CTCs did not demonstrate AK amplification. Further study is certainly needed to make any conclusions.

In summary, adding alisertib to an abiraterone regimen seems intolerable in mCRPC. The optimal dose and schedule of alisertib could not be determined. There was no clear signal indicating that alisertib might be beneficial for patients with mCRPC progressing on abiraterone, and further development of this treatment combination is not warranted.

**DISCLOSURES**

**Nancy Lewis:** Novartis (E); Massimo Cristofanilli: Dompé, Vorlex, Agenda (C/A), Pfizer (H). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (O) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

**REFERENCES**

1. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.
2. Ryan CJ, Smith MR, de Bono JS et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138–148.
3. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028–1038.
4. Dees EC, Cohen RB, von Mehren M et al. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 2012;18:4775–4784.
5. Melicher B, Adenis A, Lockhart AC et al. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: A five-arm phase 2 study. Lancet Oncol 2015;16:395–405.
6. Stein ME, Bernstein Z, Abacioglu U et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications—a retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008;336:478–488.
7. Flechon A, Pousselle D, Ferlay C et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011;22:2476–2481.
8. Berruti A, Dogliotti L, Mosca A et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001;12(suppl 2):S157–S157.
9. Sarkar D, Singh SK, Mandal AK et al. Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy. Cancer Biomark 2010;8:81–87.
10. Loriot Y, Massard C, Gross-Goupil M et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: A prospective study evaluating also neuroendocrine features. Ann Oncol 2009;20:703–708.

©AlphaMed Press 2016
11. Beltran H, Rickman DS, Park K et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011;1:487–495.

12. Aparicio A, Tzelepi V, Araujo JC et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient’s tumor: Morphological, immunohistochemical, and gene expression profiles. Prostate 2011;71:846–856.

13. Buschhorn HM, Klein RR, Chambers SM et al. Aurora-A over-expression in high-grade PIN lesions and prostate cancer. Prostate 2005;64:341–346.

14. Furukawa J, Miyake H, Takenaka A et al. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. BJU Int 2007;100:310–314.

15. Shu SK, Liu Q, Coppola D et al. Phosphorylation and activation of androgen receptor by Aurora-A. J Biol Chem 2010;285:33045–33053.
Table 2. Changes of CgA and NSE levels after treatment with alisertib

| Patient | Chromogranin A | Neuron-specific enolase |
|---------|----------------|-------------------------|
|         | Initial | End | Initial | End |
| 1       | 7       | 6.4 | 6.5     | 7.9 |
| 2       | 2.5     | 92  | 13.2    | 22.5|
| 3       | 5.8     | 1.4 | 7.2     | 5.6 |
| 4       | 4       | 3.8 | 8.1     | 5.4 |
| 5       | 3.6     | 2.14| 9.1     | <5  |
| 6       | <1      | <1  | 5.5     | 7.6 |
| 7       | 6.2     | 9.2 | 5.1     | 8.7 |
| 8       | 6       | 6   | 7.3     | <5  |
| 9       | 4.2     | 4.2 | 29.7    | 30.8|

Abbreviations: CgA, chromogranin A; NSE, neuron-specific enolase.